Glofitamab,Obinutuzumab,Tocilizumab
roche
['glofitamab', 'lymsm', 'lymphoma', 'dlbcl']
delighted that #glofitamab pivotal data for dlbcl is now online . 39.4% cr in patients with the most common aggressive #lymphoma, fixed course, durable remissions, good safety profile, i hope this data changes practice for patients with r/r #dlbcl #ash22 #lymsm 
Clinical haematologist at Peter MacCallum Cancer Centre in Melbourne. Aggressive Lymphoma Lead. MDS/AML/myeloma.Early phase trials. Views are my own.